11630 SW 97 Street, Miami, Florida 33176, US

Advertising Driven Press Release Distribution

Tag: vision

Curative Biotechnology, Inc. Names Marc Drimer, CPA to Board of Directors

Press Release
Appointment of Independent Director and Chairman of Audit Committee Expands Financial Expertise on Board Boca Raton, FL, July 20, 2021 -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for rare diseases, announced today that Marc Drimer, CPA has joined its Board of Directors as an independent director and Chairman of the Audit Committee. Mr. Drimer has over 35. Read More>>

Curative Biotechnology, Inc. Announces Ticker Symbol Change to “CUBT” on OTC Markets

Press Release
Company Appoints Kapil Bharti, Ph.D., and Dimiter Dimitrov, Ph.D. to Scientific and Clinical Advisory Board Boca Raton, FL / iCrowd Newswire/ April 29, 2021 / Curative Biotechnology, Inc.  (OTC: CUBT) a development-stage biomedical company focused on novel therapies for rare diseases, announced today the Company's trading symbol change from "CTYX" to "CUBT".  As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and. Read More>>

Will Machine Vision Market carry its growth momentum post COVID-19? Read more to know.

Press Release
Machine vision market is likely to grow at an impressive CAGR of 6.5% during the forecast period, according to a report from Stratview Research. COVID-19 pandemic – Boon or a Curse to the industry? The outbreak of COVID-19 has severely impacted several industries across the world. Tough government measures such as lockdown of major economies, has pressed the ‘pause button’ for most of the industries. For most of the industries, the revenue has. Read More>>

Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Press Release
Boca Raton, FL (Feburary 04, 2021) – Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to. Read More>>

Subscribe to Our Newsletter

For exclusive content regarding the latest trends in the world of Press Release distribution.